|In vitro (25°C)||DMSO||100 mg/mL heating (175.61 mM)|
|Water||19 mg/mL heating (33.36 mM)|
|Ethanol||<1 mg/mL (<1 mM)|
|In vivo||Saline||30 mg/mL|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||17.56 mL||87.81 mL||175.62 mL|
|0.5 mM||3.51 mL||17.56 mL||35.12 mL|
|1 mM||1.76 mL||8.78 mL||17.56 mL|
|5 mM||0.35 mL||1.76 mL||3.51 mL|
*The above data is based on the productmolecular weight 569.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
RAF265 (CHIR-265) is an oral, highly selective RAF and VEGFR kinase inhibitor, which is to control or normalize VEGFR-2 along with the inhib…
E7080 is a multi-kinase inhibitor that inhibits both VEGFR2 and VEGFR3 kinases.
SKLB1002 is a new potent VEGFR2 inhibitor, which could significantly inhibit HUVEC proliferation, migration, invasion, and tube formation.
Linifanib (ABT-869) is a structurally novel, potent inhibitor of RTK, VEGF and PDGF with IC50 of 0.2, 2, 4, and 7 nM for human endothelial c…
ZM 306416 is a VEGF receptor tyrosine kinase inhibitor that inhibits KDR (IC50 = 100 nM) and Flt (IC50 = 2 uM) tyrosine kinases.
NVP-BAW2881 is a potent and selective VEGFR inhibitor (vascular endothelial growth factor receptor tyrosine kinase inhibitor) with activity …
XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.